Niagen Bioscience financials
$2.95−1.01%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $129.4M |
| Gross profit | $83.2M |
| Gross margin | 64.3% |
| Operating income | $16.3M |
| Net income | $17.4M |
| Net margin | 13.4% |
| Diluted EPS | $0.20 |
| EBITDA | $17.1M |
| Operating cash flow | $13.5M |
| Free cash flow | $13.2M |
| Diluted shares | 85.4M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $64.8M |
| Short-term investments | $0.00 |
| Total debt | $0.00 |
| Total assets | $106.4M |
| Total liabilities | $29.9M |
| Shareholders' equity | $76.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology